What is Atelerix?
Atelerix specializes in hypothermic preservation technology designed for cryogenic shipping and extending the shelf life of fresh products. Their patented hydrogel encapsulation technology enables the storage and transport of cells at room temperature (4-25 degrees Celsius), a significant departure from traditional cryogenic methods. This innovation allows cells to maintain over 90% viability for up to 14 days at ambient temperatures, offering substantial cost reductions of 50-80% per shipment. Furthermore, Atelerix utilizes standard packaging, eliminating the need for specialized cryogenic containers and hazardous dry ice, thereby streamlining the logistics process for biological materials.
How much funding has Atelerix raised?
Atelerix has raised a total of $1M across 1 funding round:
Other Financing Round
$1M
Other Financing Round (2025): $1M with participation from ACF Investors and o2h ventures
Key Investors in Atelerix
ACF Investors
ACF Investors is a UK-based investment fund focused on supporting promising businesses through angel and co-investment, collaborating with sector-focused angels to drive capital growth.
o2h ventures
o2h ventures is a specialist UK biotech fund that supports early-stage biotech therapeutics and AI opportunities from seed to clinical success, offering SEIS/EIS and growth-stage funds.
What's next for Atelerix?
The recent major strategic investment positions Atelerix for significant scaling and market penetration. This capital infusion is expected to accelerate the development and commercialization of their preservation solutions, potentially expanding their reach into new therapeutic areas and geographical markets. The company's ability to offer cost-effective, room-temperature shipping for sensitive biologicals addresses a critical bottleneck in the life sciences supply chain, suggesting a future focused on broader adoption and strategic partnerships within the biotech and pharmaceutical industries.
See full Atelerix company page
